The ALDH1A1 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 143B human osteosarcoma cell line. These cells harbor a targeted disruption of the ALDH1A1 gene, resulting in a polyclonal pool with loss of functional aldehyde dehydrogenase 1A1 expression. By utilizing CRISPR/Cas9-mediated gene disruption, this model provides a powerful platform for investigating the loss-of-function effects of ALDH1A1 in a cancer-relevant context, avoiding clonal selection artifacts.
The 143B cell line is a well-established model of human osteosarcoma, originally derived from a primary tumor and noted for its high metastatic potential, particularly to the lungs. This aggressive cell line is widely employed in studies of bone cancer progression, invasion, and metastasis, offering a robust system to evaluate the impact of genetic alterations on malignant phenotypes in vitro and in vivo.
ALDH1A1 encodes a cytosolic aldehyde dehydrogenase that catalyzes the oxidation of retinaldehyde to retinoic acid, the ligand for nuclear receptors RAR?? and RXR??, thereby regulating gene transcription. Additionally, ALDH1A1 detoxifies reactive aldehydes and serves as a functional marker of normal and cancer stem cells. Its expression is controlled by all-trans retinoic acid, Wnt/??-catenin, Notch1, NF-??B, and FOXO1. Downstream, retinoic acid modulates target genes such as HOXA5, CYP26A1, Bcl-2, and Cyclin D1, influencing differentiation, apoptosis, and proliferation. The enzyme interacts with the cofactor NAD+ and is inhibited by disulfiram. Key pathway components linking ALDH1A1 to cellular outcomes include RAR??, RXR??, CYP26A1, HOXA5, and ??-catenin.
In osteosarcoma, ALDH1A1 is implicated in maintaining cancer stem cell self-renewal, chemoresistance, and metastatic potential, with elevated expression correlating with poor prognosis. The 143B knockout model allows dissection of ALDH1A1-specific contributions to these malignant traits. Comparative analysis of the polyclonal knockout population versus parental 143B cells enables assessment of stem cell marker expression, invasive capacity, and drug sensitivity. This model is particularly suited for exploring crosstalk between retinoic acid signaling and Wnt/??-catenin pathways in osteosarcoma metastasis.
Researchers can employ these polyclonal knockout cells in diverse experimental settings, including cancer stem cell biology, retinoic acid signaling, and chemoresistance studies. Representative assays include Western blotting, RT-qPCR, Aldefluor-based flow cytometry for ALDH activity, and migration/invasion assays. The cells are also valuable for metabolic studies of aldehyde detoxification and disulfiram-based drug sensitivity testing. This stable polyclonal pool facilitates functional genomics and elucidation of ALDH1A1-dependent pathways. For further information, contact Ascent Research.
